This study is a phase 2, single-arm, open-label, multi-institutional trial to evaluate the
efficacy of combination therapy of bortezomib, thalidomide, and dexamethasone in patients
with newly diagnosed Waldenstrom's macroglobulinemia and lymphoplasmacytic lymphoma.